Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents

References

• Modifying the Immune System in MS: What We Know What We’re LearningCounseling Points201063
   Google Scholar
• HeesenCSolariAGiordanoADecisions on multiple sclerosis immunotherapy: new treatment complexities urge patient engagementJ Neurol Sci201010.1016/j.jns.2010.09.012
   Google Scholar
• McGarveySCommunication Strategies for Interactions with MS Patients. Solutions in Mind, Optimizing PerformanceProceedings of the 1st MS Expert Nurse Summit conferenceNovember 20–21, 2010Vienna, Austria Mississauga 2010
   Google Scholar
• IyengarSThe Art of ChoosingNew YorkHachette Book Group2010
   Google Scholar
• FrohmanEPhillipsTKokelKDisease-modifying therapy in multiple sclerosis: strategies for optimizing managementThe Neurologist2002822723612803682
   PubMed Web of Science ®Google Scholar
• LipsyRJWill the newer oral MS agents be welcomed by managed care organizationsAm J Manag Care201016S227S23320873947
   PubMed Web of Science ®Google Scholar
• BrinkmannVFTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous systemBr J Pharmacol200915851173118219814729
   PubMed Web of Science ®Google Scholar
• KapposLRadueEWO’ConnorPA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med2010362538740120089952
   PubMed Web of Science ®Google Scholar
• KapposLAntelJComiGOral fingolimod (FTY720) for relapsing multiple sclerosisN Engl J Med2006355111124114016971719
   PubMed Web of Science ®Google Scholar
• CohenJABarkhofFComiGOral fingolimod or intramuscular interferon for relapsing multiple sclerosisN Engl J Med2010362540241520089954
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. NDA approval letter. September 21, 2010. GYLENIA, NDA no. 022527. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022527s000lbl.pdf. Accessed December 10, 2010.
   Google Scholar
• CarsonDAWassonDBTaetleRSpecific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytesBlood1983627377436136305
   PubMed Web of Science ®Google Scholar
• GasperiniCRuggieriSPozzilliCEmerging oral treatments in multiple sclerosis: clinical utility of cladribine tabletsTher Clin Risk Manag2010639139920856685
   PubMed Web of Science ®Google Scholar
• RieckmannPComiGCookSEffects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathegenesis: surface marker analysis for a subset of patients from the 96 week, Phase III, double-blind, placebo-controlled CLARITY study. Presented at the annual Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Dusseldorf, Germany, September 9–12, 2009Mult Scler200915S248S249
   Google Scholar
• RiceGPFilippiMComiGCladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study GroupNeurology2000541145115510720289
   PubMed Web of Science ®Google Scholar
• Bartosik-PsujekHBelniakEMitosek-SzewczykKInterleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribineActa Neurol Scand2004109639039215147461
   PubMed Web of Science ®Google Scholar
• LiliemarkJThe clinical pharmacokinetics of cladribineClin Pharmacokinet19973221201319068927
   PubMed Web of Science ®Google Scholar
• BeutlerESipeJCRomineJSThe treatment of chronic progressive multiple sclerosis with cladribineProc Natl Acad Sci U S A1996934171617208643695
   PubMed Web of Science ®Google Scholar
• RomineJSSipeJCKoziolJAA double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosisProc Assoc Am Physicians199911135449893155
   PubMedGoogle Scholar
• RuckemannKFairbanksLDCarreyEALeflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humansJ Biol Chem199827321682216919705303
   PubMed Web of Science ®Google Scholar
• O’ConnorPWLiDFreedmanMSA Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapsesNeurology200666689490016567708
   PubMed Web of Science ®Google Scholar
• ConfavreuxCO’ConnorPWFairbanksLDSafety of teriflunomide in the treatment of multiple sclerosis: results over an 8-year extensionPresented at 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)October 13–16, 2010Gothenburg, Sweden
   Google Scholar
• O’ConnorPWWolinskiJSConfavreuxCTEriflunomide Multiple Sclerosis Oral (TEMSO) Trial GroupA phase III placebo-controlled trial of oral teriflunomide in patients with relapsing forms of multiple sclerosisPresented at 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)October 13–16, 2010Gothenburg, Sweden
   Google Scholar
• PolmanCBarkhofFSandberg-WollheimMTreatment with laquinimod reduces development of active MRI lesions in relapsing MSNeurology200564698799115781813
   PubMed Web of Science ®Google Scholar
• ComiGPulizziARovarisMEffect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLancet200837196302085209218572078
   PubMed Web of Science ®Google Scholar
• ComiGAbramskyOArbizuTOral laquinimod in patients with relapsing-remitting multiple sclerosis: 9-month double-blind active extension of the multicenter, randomized, double-blind, parallel-group placebo-controlled studyMult Scler200814S37
   Google Scholar
• US Food and Drug Administration NDA approval letter. January 22, 2010. AMPYRA, NDA no. 022250. http:///www.accessdata.fda.gov/drugsatfda_docs_label/2010/022250s000REM.pdf. Accessed December 10, 2010.
   Google Scholar
• GoodmanADBrownTRKruppLBSustained-release oral fampridine in multiple sclerosis: a randomized, double-blind, controlled trialLancet2009373966573273819249634
   PubMed Web of Science ®Google Scholar
• GoodmanADBrownTREdwardsKRA phase 3 trial of extended release oral dalfampridine in multiple sclerosisAnn Neurol201068449450220976768
   PubMed Web of Science ®Google Scholar
• BergerTCurrent therapeutic recommendations in multiple sclerosisJ Neurol Sci2009287Suppl 1S37S4520106347
   PubMed Web of Science ®Google Scholar
• The Expanding Treatment Options for Multiple SclerosisProceedings of the 26th Congress of the European Committee for Treatment and Research in Multiple SclerosisOctober 13–16, 2010Gothenburg, Sweden Medical Frontiers International; 2010
   Google Scholar
• Counselling Patients on Long-term Disease-modifying TherapyCounseling Points201061
   Google Scholar
• GonsetteREMitoxantrone immunotherapy in multiple sclerosisMult Scler199613293329345411
   PubMedGoogle Scholar
• TreadawayKCutterGSalterAFactors that influence adherence with disease-modifying therapy in MSJ Neurol2009256456857619444532
   PubMed Web of Science ®Google Scholar
• Adherence to Disease-Modifying Agents in Relapsing-Remitting Multiple SclerosisInternational Journal of MS Care2010122
   Google Scholar
• TurnerAPWilliamsRMSloanAPInjection anxiety remains a long-term barrier to medication adherence in multiple sclerosisRehabil Psychol200954111612119618711
   PubMed Web of Science ®Google Scholar
• MohrDCGoodkinDELikoskyWTherapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatmentMul Scler19962222226
   PubMedGoogle Scholar
• PortaccioEZipoliVSiracusaGLong-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosisEur Neurol20085913113518057899
   PubMed Web of Science ®Google Scholar
• SheaSCImproving Medication Adherence How to Talk with Patients About Their MedicationsPhiladelphia, PAWolters Kluwer Health, Inc2006
   Google Scholar
• StuveOKnowns and unknowns in the future of multiple sclerosis treatmentJ Neurol Sci2009287Suppl 1S30S3620106346
   PubMed Web of Science ®Google Scholar
• TousignantGShawPManagement of Immunomodulating Therapies in MS CareProceedings of the 1st MS Expert Nurse Summit conferenceNovember 20–21, 2010Vienna, Austria Montreal, UK, 2010
   Google Scholar